Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rescue breathing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Rescue breathing. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-000578-31 Sponsor Protocol Number: SED002 Start Date*: 2021-01-14
    Sponsor Name:Sedana Medical AB
    Full Title: A Randomised Active-controlled Study to Compare Efficacy and Safety of Inhaled Isoflurane Delivered by the AnaConDa-S (Anaesthetic Conserving Device) to Intravenous Midazolam for Sedation in Mechan...
    Medical condition: Sedation in Mechanically Ventilated Paediatric Patients 3 to 17 (Less than 18) Years Old
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10039897 Sedation PT
    21.1 100000004865 10049683 Monitored anesthesia care sedation LLT
    21.1 100000004865 10062825 Monitored anaesthesia care sedation LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004551-67 Sponsor Protocol Number: SED001 Start Date*: 2017-04-18
    Sponsor Name:Sedana Medical AB
    Full Title: A randomised, controlled, open-label study to confirm the efficacy and safety of sedation with isoflurane in invasively ventilated ICU patients using the AnaConDa administration system
    Medical condition: Adult subjects admitted to the ICU clinically indicated to require sedation with propofol and invasive ventilation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2017-000702-38 Sponsor Protocol Number: D3250C00036 Start Date*: 2017-07-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Lon...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002163-26 Sponsor Protocol Number: D3250C00018 Start Date*: 2013-11-08
    Sponsor Name:AstraZeneca AB
    Full Title: A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequatley contr...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002345-11 Sponsor Protocol Number: D3250C00017 Start Date*: 2013-10-10
    Sponsor Name:AstraZeneca AB
    Full Title: A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase III efficacy and safety study of benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-actin...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002352-32 Sponsor Protocol Number: D3250C00016 Start Date*: 2014-02-26
    Sponsor Name:AstraZeneca AB
    Full Title: A multicentre, randomised, double-blind, paralllel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) added to medium dose inhaled corticosteroid plus long acti...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000593-19 Sponsor Protocol Number: D589UC00001 Start Date*: 2014-08-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® pMDI 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuha...
    Medical condition: Patients with moderate to very severe chronic obstructive pulmonary disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-013791-49 Sponsor Protocol Number: RHM MED 0879 Start Date*: 2009-09-23
    Sponsor Name:Southampton Universities Hospital Trust
    Full Title: Safety and Efficacy of parenteral KGF in moderate asthma subjects
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002483-40 Sponsor Protocol Number: D3741C00007 Start Date*: 2018-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, com...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003560 Asthma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002523-42 Sponsor Protocol Number: D3250C00020 Start Date*: 2014-06-24
    Sponsor Name:AstraZeneca AB
    Full Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) to reduce oral corticosteroid use in patients with uncontro...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-001704-22 Sponsor Protocol Number: CCD-05993AA1-08 Start Date*: 2015-02-25
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formote...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) PT (Completed) HU (Completed) CZ (Completed) RO (Completed) DK (Completed) DE (Completed) AT (Completed) NO (Completed) PL (Completed) FR (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003369-20 Sponsor Protocol Number: CT-P59_3.2 Start Date*: 2020-11-13
    Sponsor Name:Celltrion, Inc
    Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R...
    Medical condition: SARS CoV 2 infection in outpatients
    Disease: Version SOC Term Classification Code Term Level
    23.0 10022891 - Investigations 10084271 SARS-CoV-2 test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006980-22 Sponsor Protocol Number: TR02-105 Start Date*: 2007-06-14
    Sponsor Name:Transave, Inc.
    Full Title: MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000337-36 Sponsor Protocol Number: FSJD-GLUCOBR-2010 Start Date*: 2011-08-30
    Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU
    Full Title: IMPACT OF THE ADMINISTRATION OF SYSTEMIC GLUCOCORTICOIDS ON INFLAMMATORY RESPONSE AND CLINICAL EVOLUTION OF PATIENTS DIAGNOSED WITH MODERATE-SEVERE BRONCHIOLITIS
    Medical condition: Viral bronchiolitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004118-37 Sponsor Protocol Number: CNS7056-026 Start Date*: 2021-08-31
    Sponsor Name:PAION UK Ltd [...]
    1. PAION UK Ltd
    2. Acacia Pharma Ltd.
    Full Title: A Phase 2/3, prospective, open-label trial evaluating the efficacy, safety, and pharmacokinetics of remimazolam for intravenous sedation in paediatric patients undergoing diagnostic and/or therapeu...
    Medical condition: Paediatric procedural sedation
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004865 10083924 Sedation procedure LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002094-36 Sponsor Protocol Number: D3250C00038 Start Date*: 2016-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, U...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001360-21 Sponsor Protocol Number: CD-RI-CAT-354-1049 Start Date*: 2011-09-07
    Sponsor Name:AstraZeneca AB R&D Mölndal
    Full Title: A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001886-33 Sponsor Protocol Number: MK-8616-076-00 Start Date*: 2012-10-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Randomized, Controlled, Parallel Group, Double Blind Trial to Compare the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures Using a 2x2 Fact...
    Medical condition: Patients undergoing elective in-patient laparoscopic cholecystectomy procedures under general anesthesia with neuromuscular relaxation and active reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001916-20 Sponsor Protocol Number: 191-079 Start Date*: 2014-09-18
    Sponsor Name:Mylan Pharma UK Ltd
    Full Title: A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF...
    Medical condition: Chronic Obstructive Pulmonary Disease.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005919-51 Sponsor Protocol Number: REP0220 Start Date*: 2021-01-19
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A phase 3, double-blind, randomized, placebo-controlled, multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with severe COVID-19 pneumonia.
    Medical condition: COVID-19 Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 01 15:04:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA